5 Most Promising Long-Term Stocks to Buy According to Analysts

4. BeOne Medicines AG (NASDAQ:ONC)

Average Upside Potential: 52.88%

BeOne Medicines (NASDAQ:ONC) is one of the most promising long-term stocks to buy according to analysts. On June 1, BeOne presented new clinical data at the 2026 ASCO Annual Meeting, highlighting accelerated progress across three high-priority solid tumor development programs. The data validates the company’s strategy of pairing specific biological targets with advanced modalities, supporting the advancement of several assets toward pivotal clinical trials throughout 2026.

Key updates include promising efficacy for the CDK4 inhibitor BGB-43395 in first-line metastatic breast cancer, which will move into a Phase 3 trial this month. Additionally, the B7-H4 ADC, BG-C9074, showed encouraging results in ovarian cancer, while the GPC3x4-1BB bispecific antibody, BGB-B2033, demonstrated significant anti-tumor activity in heavily pre-treated hepatocellular carcinoma/HCC.

These findings reflect a major inflection point for BeOne Medicines’ (NASDAQ:ONC) oncology portfolio as it aims to establish new standards of care in breast, gynecologic, and gastrointestinal cancers. The company plans to leverage these results to support upcoming readouts at future medical congresses and continue its rapid development of these differentiated therapeutic candidates.

BeOne Medicines (NASDAQ:ONC) is a global oncology company that discovers and develops innovative treatments that are more affordable and accessible to cancer patients worldwide.